Shenzhen University General Hospital
Shenzhen University General Hospital
Explore linked clinical trials.18 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | Albuminuria, Body Weight, Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Nutritional and Metabolic Diseases, Overweight, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, chronic renal failure syndrome, kidney disorder, kidney failure, nutritional disorder, obesity disorder, overnutrition, proteinuria, urinary system disorder | Not yet recruiting | Not applicable | 2026-09-30 | NCT07849348 | |
| Phase I Clinical Study of Haplo-HSCT Combined With Hypoxic 3D-Cultured Umbilical Cord MSC for the Treatment of SAA | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, bone marrow disorder, hematologic disorder | Enrolling by invitation | Phase 1 / Phase 2 | 2026-06-23 | NCT07299123 | |
| Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor Cell Lymphoblastic Leukemia-Lymphoma, acute myeloid leukemia, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, myeloid leukemia, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-13 | NCT07584889 | |
| Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia | Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-05-01 | NCT07563179 | |
| Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-04-02 | NCT07508605 | |
| Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Not yet recruiting | Phase 4 | 2026-02-18 | NCT07417696 | |
| Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease | Crohn disease, Digestive System Diseases, digestive system disorder, gastroenteritis, inflammatory bowel disease, intestinal disorder | Not yet recruiting | Phase 4 | 2026-02-17 | NCT07415473 | |
| Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors | Advanced Solid Malignant Tumors (With Positive Expression of MSLN in Tumor Tissue) | Recruiting | Phase 1 / Phase 2 | 2026-02-10 | NCT07399769 | |
| The Association Between Core Temperature and Health | Body Temperature Changes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms | Recruiting | Not applicable | 2026-01-21 | NCT06432491 | |
| Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | Neoplasms by Histologic Type, adenocarcinoma, carcinoma, cholangiocarcinoma, epithelial neoplasm, intrahepatic cholangiocarcinoma, neoplasm | Active, not recruiting | Phase 2 / Phase 3 | 2025-09-04 | NCT04669496 | |
| Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL) | acute myeloid leukemia | Enrolling by invitation | Early phase 1 | 2025-08-28 | NCT06499025 | |
| Efficacy and Safety of CD19CD20-CAR.p40-T in B-cell Lymphoma | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2025-07-31 | NCT07097207 | |
| BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 / Phase 2 | 2024-10-16 | NCT06644443 | |
| Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2024-02-02 | NCT06234072 | |
| Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T | Advanced Gastric Carcinoma; Advanced Pancreatic Carcinoma | Recruiting | Not applicable | 2022-11-22 | NCT05620732 | |
| Study of GPC-3 CAR-T Cells in Treating With Hepatocellular Carcinoma | Advanced Hepatocellular Carcinoma | Recruiting | Not applicable | 2022-11-22 | NCT05620706 | |
| Study of NY-ESO-1 TCR-T in Advanced Soft Tissue Sarcoma | Advanced Soft-tissue Sarcoma | Recruiting | Not applicable | 2022-11-22 | NCT05620693 | |
| CD7 CAR-T Cells in T-cell Lymphoma/Leukemia | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, T lymphoblastic leukemia/lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Not applicable | 2022-11-17 | NCT05620680 |